|
|
Diphtheria Antitoxin Equine DI. |
16/166 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
Anti-Typhoid capsular Vi polysaccharide Ig (Human) 1st WHO International Standard |
16/138 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
Native Vi polysaccharide (S. Typhi) |
16/126 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
WHO 1st International Reference Panel for Genomic JAK2 V617F |
16/120 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
HHV-6 Virus 1st WHO International Standard |
15/266 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
Anti- EBOV Convalescent Plasma Pool - Sierra Leone (International Reference Reagent) |
15/262 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
Erythropoietin Antibody Reference Panel B (1st WHO Reference Panel) |
15/242 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
Erythropoietin Antibody Reference Panel A (1st WHO Reference Panel) |
15/240 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
EBOV RNA VP40-L (WHO Reference Reagent) |
15/224 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
EBOV RNA NP-VP35-GP (WHO Reference Reagent) |
15/222 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
Anti-EBOV plasma, human (WHO Reference Reagent) |
15/220 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
Blood Coagulation Factor XI, Plasma Human (2nd International Standard) |
15/180 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
Lupus (oligo-specific) anti-dsDNA antibodies WHO Reference Reagent |
15/174 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
EBOV RNA VP40-L in-run control |
15/138 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
EBOV RNA NP-VP35-GP in-run control |
15/136 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
Ancrod |
15/106 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
Factor IX activated (FIXa) 2nd WHO International Standard |
14/316 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
High titre anti-A and anti-B in serum (WHO Reference Reagent). |
14/300 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
BK Virus (BKV)(1st International Standard) |
14/212 |
|
|
4-6周 |
|
|
￥0.00 |
|
|
|
Biological activities of Rituximab WHO 1st International Standard |
14/210 |
|
|
4-6周 |
|
|
￥0.00 |
|
